Evidence map›Paper›PMID 29284465›Full record

Trial reportBMC complementary and alternative medicine2017

Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial.

Yujie Jia, Xuezhu Zhang, Jianchun Yu, Jingxian Han, Tao Yu, Jiangwei Shi, Lan Zhao, Kun Nie

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC complementary and alternative medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Efficacy of Acupuncture Therapy for Chemotherapy-Related Cognitive Impairment in Breast Cancer Patients.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Trial
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yujie JiaFirst Teaching Hospital of Tianjin University of Traditional ChineseMedicine, Tianjin, 300193, China.
Xuezhu ZhangFirst Teaching Hospital of Tianjin University of Traditional ChineseMedicine, Tianjin, 300193, China.
Jianchun YuFirst Teaching Hospital of Tianjin University of Traditional ChineseMedicine, Tianjin, 300193, China. yujianchun1964@126.com.
Jingxian HanFirst Teaching Hospital of Tianjin University of Traditional ChineseMedicine, Tianjin, 300193, China.
Tao YuFirst Teaching Hospital of Tianjin University of Traditional ChineseMedicine, Tianjin, 300193, China.
Jiangwei ShiFirst Teaching Hospital of Tianjin University of Traditional ChineseMedicine, Tianjin, 300193, China.
Lan ZhaoFirst Teaching Hospital of Tianjin University of Traditional ChineseMedicine, Tianjin, 300193, China.
Kun NieFirst Teaching Hospital of Tianjin University of Traditional ChineseMedicine, Tianjin, 300193, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is the most common cause of dementia. However, none of medical treatment can stop or reverse the underlying neurodegenerative of AD at present. Acupuncture has attracted more and more attention in recent years due to its efficacy and very few side effects. Lately, a systematic review has thought that the evidence on the effectiveness of acupuncture in improving the cognitive function of AD patients was not powerful enough. Therefore, the aim of this study is to explore the efficacy and safety of acupuncture in patients with mild to moderate AD.

methodsThis was a randomized, controlled, parallel-group, exploratory study with 4-week baseline (T0), 12-week treatment phase (T1) and 12-week follow-up period (T2). Patients with mild to moderate AD meeting the included criteria were randomly allocated into either acupuncture or donepezil hydrochloride groups. The acupuncture group(AG) was given acupuncture treatment three times per week and the donepezil hydrochloride group(DG) group was administered donepezil hydrochloride once daily (5 mg/day for the first 4 weeks and 10 mg/day thereafter). Primary efficacy was measured using Alzheimer's disease Assessment Scale-Cognitive (ADAS-cog) and Clinician's Interview-Based Impression of Change-Plus (CIBIC-Plus). The second outcomes were measured with 23-Item Alzheimer's disease Cooperative Study Activities of Daily Living Scales (ADAS-ADL

resultsOf 87 participants enrolled in the study, 79 patients finished their treatment and follow-up processes. The ADAS-cog scores for AG group showed obvious decreases at T2 and ∆(T2-T0)when compared with DG group, and significant between-group differences were detected (all p < 0.05). The mean CIBIC-Plus values for the AG group at T1 and T2 were much lower than that for the DG group, and there were significant differences between the two groups (푃<0.05). There were no significant between-group differences in the scores of ADAS-ADL

conclusionsAcupuncture is safe, well tolerated and effective in improving the cognitive function, global clinical status of AD.

trial registrationChiCTR-IOR-17010465 (Retroactively registered on 18 JAN 2017).

Indexed as

Acupuncture TherapyAgedAged, 80 and overAlzheimer DiseaseDonepezilFemaleHumansIndansMaleMental Status and Dementia TestsPiperidinesTreatment OutcomeDonepezilIndansPiperidinesAcupunctureAlzheimer’s diseaseRandomized controlled trial

Identifiers

PMID29284465
PMCPMC5747102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.